Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 3/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200519 | 0.85 | MAP2K1 (0.36) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL3601959 | 0.85 | MAP2K1 (0.36) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL2363030 | 0.84 | NTRK1 (0.43) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL3082604 | 0.84 | MAP2K1 (0.49) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL3090230 | 0.81 | NTRK1 (0.47) | PARP10NTRK1PIM1JAK1 | |
| SCHEMBL3594492 | 0.81 | NTRK1 (0.34) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL2730821 | 0.81 | MAP2K1 (0.34) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL2365057 | 0.81 | MKNK1 (0.40) | MAP2K1CLK4DYRK1BJAK2JAK1 | |
| SCHEMBL2362508 | 0.78 | MAP2K1 (0.36) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL3593157 | 0.77 | TAAR1 (0.38) | MAP2K1CLK4DYRK1BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2021-12-02 | — | — | US | disclosed |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2021-05-11 | — | — | US | disclosed |
| US-20200078365-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2020-03-12 | — | — | US | disclosed |
| US-10328081-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-06-25 | — | — | US | disclosed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20180000831-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2018-01-04 | — | — | US | disclosed |
| US-9707237-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| EP-3178819-A1 | 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | Galapagos NV (BE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2445911-B1 | 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2017-03-01 | — | — | EP | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2014-04-10 | — | — | US | disclosed |
| US-8563545-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2013-10-22 | — | — | US | disclosed |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2012-06-07 | — | — | US | disclosed |
| EP-2445911-A1 | 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | Galapagos N.V. (BE) | 2012-05-02 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078365-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-10328081-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, JAK2 | MAP2K1 2449/4885CLK4 2612/4885DYRK1B 2932/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | MAP2K1 2241/4885CLK4 2179/4885DYRK1B 3767/4885 |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-20180000831-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | MAP2K1 3050/4885CLK4 3271/4885DYRK1B 3184/4885 |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | MAP2K1 2963/4885CLK4 2604/4885DYRK1B 2231/4885 |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | MAP2K1 3050/4885CLK4 3271/4885DYRK1B 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.